Aprea Therapeutics (APRE) provided an update on its existing patent portfolio. Aprea’s ATR inhibitor program is protected by ...

宾夕法尼亚州多伊尔斯镇 - 市值2,120万美元的生物制药公司Aprea Therapeutics, Inc. (NASDAQ: APRE)宣布更新其专利组合。该公司专注于开发针对癌细胞脆弱性的治疗方案。根据 InvestingPro 数据显示，公司股票目前交易价格为3.90美元，年初至今上涨18.54%。公司总裁兼首席执行官Oren ...

DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) has announced significant advancements in its intellectual property ...

Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while ...

DOYLESTOWN, Pa. - Aprea Therapeutics, Inc. (NASDAQ: NASDAQ:APRE), a biopharmaceutical company with a market capitalization of $21.2 million focused on developing treatments targeting cancer cell ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

H.C. Wainwright reaffirmed its Buy rating and $20.00 stock price target for Aprea Therapeutics (NASDAQ:APRE), a biopharmaceutical company focused on developing and... Aprea Therapeutics Announces ...

Aprea Therapeutics has a 12-month low of $2.15 and a 12-month high of $8.85. Get Aprea Therapeutics alerts: Aprea Therapeutics (NASDAQ:APRE – Get Free Report) last released its quarterly ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Aprea Therapeutics (APRE – Research Report) and keeping the price target at $20.00. Discover outperforming stocks and ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.